Background Evidence on overall survival (OS) with cyclin‐dependent kinase 4 and 6
(CDK4/6) inhibitors is generally limited to data from clinical trials or a few observational …

De novo metastatic breast cancer (dnMBC) accounts for~ 6–10% of all breast cancers and
for~ 30% of MBC with increasing incidence over time. Hormone receptor-positive/human …

Background Because of the phenomenal success of treatment with monoclonal antibodies
and antibody‐drug conjugates targeting human epidermal growth factor receptor 2 (HER2) …

PURPOSE Given the heterogeneity and improvement in outcomes for metastatic breast
cancer (MBC), we developed a staging system that refines prognostic estimates for patients …

Purpose We sought to assess survival outcomes of patients with de novo metastatic breast
cancer (dnMBC) who did not receive treatment irrespective of the reason. Methods Adults …

Abstract Treatment for breast cancer, including endocrine therapies, can contribute to bone
loss and increase the risk of osteoporosis and fractures. Management of bone health in …

Purpose Many patients with metastatic cancer live years beyond diagnosis, and there
remains a need to improve the therapeutic ratio of metastasis-directed radiation for these …

As genetic testing becomes increasingly more accessible and more applicable with a
broader range of clinical implications, it may also become more challenging for breast …

Abstract Nuclear receptor coactivator 7 (NCOA7) is an estrogen receptor binding protein. Its
role in breast cancer progression has so far remained elusive. The present study aimed to …

In this study, a novel molecularly imprinted polymer (MIP) was synthesized with attapulgite
(ATP) and acrylamide (AM) and ethyl methacrylate (MMA) for controlled release carrier of 5 …